Total Payments
$86,027
2024 Payments
$750.00
Companies
9
Transactions
52
Payment Breakdown by Category
Consulting$45,020 (52.3%)
Research$21,853 (25.4%)
Other$16,625 (19.3%)
Travel$1,608 (1.9%)
Education$574.00 (0.7%)
Food & Beverage$346.85 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $45,020 | 22 | 52.3% |
| Unspecified | $21,853 | 2 | 25.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,125 | 8 | 14.1% |
| Honoraria | $3,000 | 1 | 3.5% |
| Travel and Lodging | $1,608 | 11 | 1.9% |
| Grant | $1,500 | 1 | 1.7% |
| Education | $574.00 | 1 | 0.7% |
| Food and Beverage | $346.85 | 6 | 0.4% |
Payments by Type
General
$64,174
50 transactions
Research
$21,853
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $29,120 | 7 | $0 (2022) |
| Celgene Corporation | $14,632 | 13 | $0 (2020) |
| Janssen Scientific Affairs, LLC | $11,646 | 9 | $0 (2024) |
| PFIZER INC. | $9,587 | 5 | $0 (2023) |
| Lilly USA, LLC | $8,338 | 2 | $0 (2020) |
| AbbVie Inc. | $8,058 | 11 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $2,620 | 2 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | 1 | $0 (2019) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $26.92 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $750.00 | 1 | Janssen Scientific Affairs, LLC ($750.00) |
| 2023 | $5,075 | 3 | PFIZER INC. ($3,000) |
| 2022 | $6,013 | 4 | Janssen Scientific Affairs, LLC ($2,200) |
| 2021 | $27,178 | 4 | Eli Lilly and Company ($21,028) |
| 2020 | $16,830 | 11 | Lilly USA, LLC ($8,338) |
| 2019 | $8,116 | 4 | Celgene Corporation ($2,866) |
| 2018 | $9,147 | 9 | Janssen Scientific Affairs, LLC ($3,196) |
| 2017 | $12,918 | 16 | AbbVie, Inc. ($4,738) |
All Payment Transactions
52 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/26/2024 | Janssen Scientific Affairs, LLC | REMICADE (Biological) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Immunology | ||||||
| 07/10/2023 | PFIZER INC. | XELJANZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/14/2023 | Janssen Scientific Affairs, LLC | REMICADE (Biological) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Immunology | ||||||
| 01/24/2023 | AbbVie Inc. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $975.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/30/2022 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| 06/27/2022 | Janssen Scientific Affairs, LLC | REMICADE (Biological) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Immunology | ||||||
| 03/25/2022 | Janssen Scientific Affairs, LLC | REMICADE (Biological) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Immunology | ||||||
| 01/13/2022 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,637.50 | General |
| 10/22/2021 | PFIZER INC. | XELJANZ (Drug) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/05/2021 | Janssen Scientific Affairs, LLC | REMICADE (Biological) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Immunology | ||||||
| 05/03/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $21,028.00 | Research |
| Study: MULTICENTER, OPEN-LABEL PK STUDY OF MIRIKIZUMAB IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | ||||||
| 03/03/2021 | AbbVie Inc. | — | Grant | Cash or cash equivalent | $1,500.00 | General |
| 12/16/2020 | AbbVie Inc. | HUMIRA (Biological) | — | Cash or cash equivalent | $825.00 | Research |
| Study: P11-292 • Category: IMMUNOLOGY | ||||||
| 12/15/2020 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,537.50 | General |
| 11/20/2020 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $3,987.50 | General |
| 10/22/2020 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $982.50 | General |
| 09/24/2020 | Celgene Corporation | ZEPOSIA (Drug) | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| Category: Neuroscience | ||||||
| 09/23/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/14/2020 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $4,350.00 | General |
| 02/28/2020 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $156.00 | General |
| Category: Neuroscience | ||||||
| 02/28/2020 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $16.00 | General |
| Category: Neuroscience | ||||||
| 01/30/2020 | Celgene Corporation | ZEPOSIA (Drug) | Education | In-kind items and services | $574.00 | General |
| Category: Neuroscience | ||||||
| 01/29/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/12/2019 | Janssen Scientific Affairs, LLC | REMICADE (Biological) | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| Category: Immunology | ||||||
| 06/14/2019 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MULTICENTER, OPEN-LABEL PK STUDY OF MIRIKIZUMAB IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | Eli Lilly and Company | $21,028 | 1 |
| P11-292 | AbbVie Inc. | $825.00 | 1 |
About Dr. Robert Baldassano, M.D
Dr. Robert Baldassano, M.D is a Pediatrics healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1104847961.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Baldassano, M.D has received a total of $86,027 in payments from pharmaceutical and medical device companies, with $750.00 received in 2024. These payments were reported across 52 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($45,020).
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatric Gastroenterology
- Location Philadelphia, PA
- Active Since 07/21/2006
- Last Updated 04/15/2013
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1104847961
Products in Payments
- REMICADE (Biological) $11,646
- XELJANZ (Drug) $9,587
- Otezla (Drug) $6,149
- Humira (Biological) $4,758
- ZEPOSIA (Drug) $4,121
- GED-0301 (Drug) $2,976
- RINVOQ (Biological) $975.00
- HUMIRA (Biological) $825.00
- TRULANCE (Drug) $26.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Philadelphia
Matthew Gillespie, M.d, M.D
Pediatrics — Payments: $1.5M
Pediatrics $1.5M
Stephan Grupp, M.d, M.D
Pediatrics — Payments: $472,209
Pediatrics $472,209
Oscar Mayer, M.d, M.D
Pediatrics — Payments: $270,148
Pediatrics $270,148
Robert Shaddy, Md, MD
Pediatrics — Payments: $148,516
Pediatrics $148,516
Michael Levine, Md, MD
Pediatrics — Payments: $137,530
Pediatrics $137,530
Michael Grunstein, M.d, M.D
Pediatrics — Payments: $133,646
Pediatrics $133,646